コンテンツへスキップ
Merck

ABE154

Anti-Histone H3.1 Antibody

rabbit polyclonal

別名:

Histone H3.1, Histone H3/a, Histone H3/b, Histone H3/c, Histone H3/d, Histone H3/f, Histone H3/h, Histone H3/I, Histone H3/j, Histone H3/k, Histone H3/l

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する

この商品について

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Clone:
polyclonal
Species reactivity:
human, mouse
Application:
ChIP, WB
Citations:
10
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします


製品名

Anti-Histone H3.1/H3.2 Antibody, from rabbit, purified by affinity chromatography

biological source

rabbit

Quality Segment

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

human, mouse

technique(s)

ChIP: suitable (ChIP-seq), western blot: suitable

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... HIST1H3F(8968)

General description

Histone H3.1 and H3.2 are closely related histone variants that differ by only one amino acid. Mammalian cells express three major types of noncentromeric histone H3 variants, H3.1, H3.2, and H3.3. H3.1 is only expressed in mammals, while H3.2 is found in all eukaryotes except for yeast. Recent evidence shows that these nearly identical histone proteins differ in their expression profiles and post-translational modifications (PTMs). H3.2 is enriched in modifications associated with transcriptional silencing (di- and tri-methylation of K27), whereas H3.1 is enriched in both K9 dimethylation and K14 acetylation, suggesting that these variants may have separate biological functions.
~17 kDa observed. Uncharacterized bands may be observed at ~25 kDa and ~50 kDa

Immunogen

KLH-conjugated linear peptide corresponding to human Histone H3.1 and H3.2.

Application

Anti-Histone H3.1/H3.2 Antibody is a highly specific rabbit polyclonal antibody, that targets Histone H3 & has been tested in western blotting & ChIP-seq.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Histones
Western Blotting Analysis: A representative lot detected Histone H3.2 in recombinant Histone H3.2 and mouse Embryonic Stem cell lysates.

Chromatin Immunprecipitation: A representative lot detected Histone H3.2 in mouse Embryonic Stem cell lysates (Elsasser, S. Graduate Thesis (http://hdl.handle.net/10209/440), Laboratory of Prof. David Allis, Rockefeller University).

Chromatin Immunoprecipitation Sequencing: A representative lot detected Histone H3.1/H3.2 in mouse Embryonic Stem cell lysates (Elsasser, S. Graduate Thesis (http://hdl.handle.net/10209/440), Laboratory of Prof. David Allis, Rockefeller University).

Biochem/physiol Actions

This antibody is expected to demonstrate broad species reactivity.

Physical form

Affinity purified
Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Preparation Note

Stable for 1 year at 2-8°C from date of receipt.

Analysis Note

Control
HeLa acid extract
Evaluated by Western Blotting in HeLa acid extract.

Western Blotting Analysis: 0.5 µg/mL from a representative lot detected Histone H3.1 and H3.2 in 10 μg of HeLa acid extract.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

Explore all of our products under Anti-Histone H3.1/H3.2 Antibody

または

製品選択ツール}で選択肢を絞り込んでください。


保管分類

12 - Non Combustible Liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

ABE154:

jan



試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする


関連コンテンツ

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).






グローバルトレードアイテム番号

カタログ番号GTIN
ABE15404053252859960